RCS - Creo Medical Group - Microwave Lung Ablation Update

Creo MedicalAnnouncement

01/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA0681Fa&default-theme=true

RNS Number : 0681F  Creo Medical Group PLC  01 March 2024

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Microwave Lung Ablation Update

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces progress with its MicroBlate Flex device.

 

Professor Pallav Shah and Dr Christopher Orton, of the Royal Brompton
Hospital, have become the first specialists in the world to perform a robotic
guided microwave ablation of lung tissue in the same sitting as a diagnostic
procedure. Creo's MicroBlate Flex device was used to perform the procedure.

 

In a recent announcement, Professor Shah and his team reported that microwave
ablation was used to ablate a 27mm cancerous nodule in a patient's lung. The
procedure took place at the Royal Brompton Hospital in London and is reported
to have taken 3 minutes.

 

Dr Orton commented: "The potential to combine the diagnosis, staging and
treatment of lung cancer in one procedure offers significant benefit to
patients."

 

Link: https://www.rbhh-specialistcare.co.uk/news/ion-robot-lung-tumour
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rbhh-specialistcare.co.uk%2Fnews%2Fion-robot-lung-tumour&data=05%7C02%7CRichard.Craven%40creomedical.com%7Cad608403fa984b290f4808dc383da3b8%7Cca1e060e3b3c4b83af940054ad5e939c%7C1%7C0%7C638447084617169835%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=wodTlr2B%2Fru3bJphuOMXxMnMXfRbjMYRQ8oNbEv3DLI%3D&reserved=0)

 

Craig Gulliford, Chief Executive Officer of Creo, said: "Creo has been
pioneering minimally invasive surgical endoscopy for pre-cancer and cancer
patients for years, and implementing our technology into robotic application
is a key goal for us as the adoption of this technology continues to grow
exponentially.

 

"We are incredibly proud that our MicroBlate Flex technology has been able to
make this world-first possible. The potential for these technologies to
combine precise robotically guided lung cancer diagnosis with the ablation of
cancerous tissue in one session is transformational. Not only could this
dramatically improve outcomes for lung cancer patients, but it has the
potential to do away with long and worrying delays between diagnosis and
treatment. This is the beginning of an exciting program and the team have done
a terrific job in reaching this point."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cavendish Capital Markets Limited                  +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                      +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR                                        Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                           Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                   +44 (0)7867 984 082

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUCCPUPCPPB